Results 161 to 170 of about 489,131 (311)

Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight

Clinical Endocrinology, Volume 104, Issue 2, Page 130-138, February 2026.
ABSTRACT Objective Bone is a target for diabetic complications, but the impact of metabolic changes on bone metabolism is less understood. Bones participate in energy metabolism by via secreted osteokines. Glucose ingestion reduces bone resorption, but the effects on osteokines remain unknown. Further, it is not known whether the response is altered in
Niki Jalava, Terhi J. Heino, Pirjo Nuutila, Kirsi A. Virtanen, Kaisa K. Ivaska   +4 more
wiley   +1 more source

Modulation of airway inflammation and resistance in mice by a nicotinic receptor agonist [PDF]

, 2005
M-R. Blanchet, Évelyne Israël-Assayag, Yvon Cormier   +2 more
openalex   +1 more source

Nicotinic Agonist [PDF]

, 2020
openaire   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 214-226, February 2026.
Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki   +4 more
wiley   +1 more source

Heterologous expression and nonsense suppression provide insights into agonist behavior at α6β2 nicotinic acetylcholine receptors

, 2015
Michael R. Post, Walrati Limapichat, Henry A. Lester, Dennis A. Dougherty   +3 more
openalex   +2 more sources

A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia

British Journal of Pharmacology, 2013
Bopanna I. Kalappa, F. Sun, S. R. Johnson, K. Jin, Victor V Uteshev   +4 more
semanticscholar   +1 more source

Deletion of the TRPV1 channel attenuates afferent renal nerve responses to renal artery occlusion but not elevated renal pelvic pressure

The Journal of Physiology, Volume 604, Issue 3, Page 1415-1427, 1 February 2026.
Abstract figure legend Using wild‐type and Trpv1−/− rats, we assessed the contribution of TRPV1 channels to the activation of afferent renal nerve activity (ARNA) during renal artery occlusion, graded reductions in renal blood flow and elevated renal pelvic pressure.
Jacob B. Sullivan, Leon J. DeLalio, Sean D. Stocker   +2 more
wiley   +1 more source

Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men

, 2007
Ann Olincy, Karen E. Stevens
openalex   +1 more source

In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model

British Journal of Pharmacology, 2013
K. Freitas, S. Negus, F. Carroll, M. Damaj   +3 more
semanticscholar   +1 more source